• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Update: ACIP 2024 Adult Immunization Recommendations

Feature
Slideshow

This summary of updates to the ACIP 2024 Adult Vaccination recommendations includes 4 new vaccines and new formulations for COVID-19 and influenza shots.

This summary of the Advisory Committee on Immunization Practices 2024 Adult Immunization Schedule,1 approved and released by the Centers for Disease Control and Prevention in January 2024, highlights 4 new vaccines, new recommendations,2 and subsequent developments that include new COVID-19 vaccine targeted strain and updated RSV vaccine recommendations.

References
1. Centers for Disease Control and Prevention, US Department of Health and Human Services. Recommended Adult Immunization Schedule2024. Accessed July 15, 2024. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html
2. Advisory Committee on Immunization Practices (ACIP). ACIP Recommendations. June 28, 2024. Accessed July 15, 2024. https://www.cdc.gov/vaccines/acip/recommendations.html

Related Content
Pneumococcal 21-Valent Conjugate Vaccine in At-Risk Adults: Daily Dose / image credit: ©New Africa/AdobeStock

Pneumococcal 21-Valent Conjugate Vaccine in At-Risk Adults: Daily Dose

Sydney Jennings
October 30th 2024
Article

Your daily dose of the clinical news you may have missed.

Investigational RSV Vaccine Yields Positive Preliminary Data in Head-to-Head Comparison with Arexvy / Image credit: ©MargJohnsonVA/AdobeStock

Investigational RSV Vaccine Yields Positive Preliminary Data in Head-to-Head Comparison with Arexvy

Sydney Jennings
October 29th 2024
Article

Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.

Tsuboya

ACIP Recommends 2nd COVID-19 Shot for Older Adults, Immunocompromised Individuals

Sydney Jennings
October 24th 2024
Article

CDC Director Mandy Cohen endorsed the ACIP's recommendations, which also call for flexible dosing under shared clinical decision making.

ACIP Supports Lowering Age for Pneumococcal Vaccination to 50 Years / image credit ©CDC

ACIP Supports Lowering Age for Pneumococcal Vaccination to 50 from 65 Years

Grace Halsey
October 24th 2024
Article

The expanded recommendation includes shots from Merck (PCV21) and Pfizer (PCV20), and could be a "practice-changing milestone," one executive said.

FDA Expands Indication for RSV Vaccine Abrysvo to Include Adults Aged 18 to 59 with Chronic Conditions

FDA Expands Indication for RSV Vaccine Abrysvo to Include Adults Aged 18 to 59 with Chronic Conditions

Grace Halsey
October 23rd 2024
Article

Pfizer announced the FDA approval on October 22 that makes Abrysvo now the RSV immunization with the broadest indication for adults, the company said.

FDA Updates Flublok Label with Safety Data for Pregnant Individuals / image credit pregnancy vaccination concept / ©Dmitry Naumov/stock.adobe.com

FDA Updates Flublok Label with Safety Data for Pregnant Individuals

Grace Halsey
October 23rd 2024
Article

The safety data used to update the Flublok label is from a study of more than 48 000 pregnant women across multiple flu seasons, according to Sanofi.

© 2024 MJH Life Sciences

All rights reserved.